LONDON (Alliance News) - Scancell Holdings PLC said Tuesday that new data shows its SCIB2 Immunobody vaccine in development for lung, oesophageal, prospate and other cancers, when combined with a checkpoint inhibitor, shows enhanced tumour destruction and longer survival times than when used alone.
The data comes from a study of animals treated with the combination treatment of a CLTA-4 blockade and SCIB2, where higher doses of tumour cells were used.
The combination resulted in a "significant survival advantage" over either individual treatment, and Scancell said that whilst patients with a relatively low tumour burden may benefit from SCIB2 alone, the results highlight the potential benefits of the combination.
"The rationale for combining Scancell's ImmunoBody vaccines with checkpoint inhibitors is gathering momentum. Whilst we believe that SCIB2, like SCIB1, will provide effective stand-alone treatment in the adjuvant setting, these data further support the hypothesis that some patients with more bulky disease will benefit from a combination of SCIB2 with CTLA-4 blockade," said Joint Chief Executive Officer Lindy Durrant in a statement.
Shares in Scancell are trading up 4.0% at 25.35 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)